CRISPR: Should there be limits on genome editing?
10th Josep Egozcue Lectures
This year's Josep Egozcue Lectures will consider a controversial and highly topical issue. New genome editing techniques such as CRISPR open up a whole range of opportunities for improving the health of individuals, but the possibilities don't end there. The technique, which involves cutting DNA to provide a rapid and precise method of correcting defective genes, can be applied to human health to cure diseases but also offers the possibility of 'improving' the characteristics of those who have yet to be born, and has a range of potential applications in animal species and in the environment.
The Grífols Foundation will be addressing this issue with a group of experts who will help us to understand what the technique involves, explain how CRISPR is already being applied and how it might be applied in the future, and help us to explore our main concern: the ethical issues that this raises. The event will include contributions from Nuffield Council on Bioethics, which has recently published a document on this topic, and Salvador Macip, doctor and
researcher at the University of Leicester, along with a line-up of speakers who are all experts in this area.
Our ability to manipulate the genome has already passed from the realm of science fiction into reality. The question is whether we wish to restrict its use to curing or modifying damage, or whether this capacity should also be used to 'improve' individuals and species. Who should have the right to make such decisions? Should we impose limits on them?
- Victòria Camps, President of the Víctor Grífols i Lucas Foundation
- Carlo Carolis, Head of the Biomolecular Screening and Protein Technology Unit, CRG
- Salvador Macip, doctor and researcher, Director of the Mechanisms of Cancer and Ageing Lab, University of Leicester
- Peter Mills, Assistant Director, Nuffield Council on Bioethics
- Pere Puigdomènech, Research Professor, CSIC. Centre for Research in Agricultural Genomics. Bellaterra
- Jesús Purroy, biomedicine entrepreneur, founder of Àvida Biotech, S.L
- Miquel-Àngel Serra, Ph.D. in Biology and research manager at the Neuropharmacology Laboratory, Pompeu Fabra University
- Núria Terribas, Director of the Víctor Grífols i Lucas Foundation
- Anna Veiga, Researcher at CMRB and Instituto de la Mujer Dexeus
*There will be simultaneous interpretation between English and Catalan.
Free registration Those wishing to attend must register in advance at: www.fundaciogrifols.org